• Acetylcholine Chloride for Gut–Brain Assays

  2026-09-24

  Use Acetylcholine Chloride as a controllable probe of cholinergic responses in gut–vagus–brain experiments—not as a stand-in for microbial treatment or endogenous neurotransmitter release. This workflow pairs practical concentration screening with circuit-level controls to help distinguish receptor responsiveness from whole-pathway effects.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib

  2026-09-24

  This study links elevated TRIB3 with adverse outcomes in clear cell renal cell carcinoma (ccRCC) and reports that TRIB3 knockdown promotes ferroptosis while increasing cellular sensitivity to sunitinib. The findings point to the SLC7A11/GPX4 antioxidant pathway as a mechanistic connection, while leaving important questions about in vivo efficacy and clinical translation unresolved.

• Pazopanib Hydrochloride: Beyond a Viability Readout

  2026-09-23

  Pazopanib Hydrochloride (GW786034) is a multi-target kinase inhibitor whose in vitro effects cannot be fully described by a single viability value. This article connects its pharmacology to a practical framework for separating growth arrest from cell killing and choosing assays that answer distinct research questions.

• PD 173074: From Mechanism to Translation

  2026-09-23

  PD 173074 is a selective FGFR1 and VEGFR2 research tool that connects ATP-competitive kinase inhibition with neuronal, vascular, and tumor phenotypes. This thought-leadership guide explains how to validate pathway causality, manage cross-domain translation, and use PD-173074 strategically in cancer research and angiogenesis studies.

• Pazopanib Hydrochloride: Readouts That Resolve Response

  2026-09-22

  Pazopanib Hydrochloride is a powerful model for studying how kinase inhibition produces growth arrest, cell death, and anti-angiogenic effects. This article applies a response-phenotyping framework to GW786034 experiments, helping researchers select more informative assays than viability alone.

• Dual HER2–VEGFR2 Targeting in TNBC

  2026-09-22

  The reference study evaluates lapatinib and Telatinib as a dual tyrosine kinase inhibition strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its phenotype-centered results link treatment with reduced proliferation, invadopodia formation, and two-dimensional angiogenic tube formation, while leaving target engagement, pharmacological synergy, and in vivo efficacy unresolved.

• Chrysin Sensitizes RCC to Sunitinib via Ferroptosis

  2026-09-21

  A November 2025 study reports that chrysin increases renal cell carcinoma sensitivity to Sunitinib by suppressing PI3K/Akt signaling and reducing SLC7A11 and GPX4, thereby promoting ferroptosis. Its combination of network pharmacology, molecular docking, functional assays, and pathway-rescue experiments provides a mechanistic framework for studying Sunitinib resistance, while remaining preclinical and primarily cell-based.

• Phosbind Acrylamide: Reading Phosphorylation States

  2026-09-21

  Phosbind Acrylamide enables antibody-free protein phosphorylation analysis by converting phosphate-dependent binding into measurable SDS-PAGE mobility shifts. This guide explains the chemistry, assay decisions, and HBV capsid workflow that determine when phosphate-affinity electrophoresis is most informative.

• AAL-993: From VEGFR Potency to Assay Design

  2026-09-20

  AAL-993 is a selective VEGF receptor inhibitor with a distinctive VEGFR-2/3 potency profile. This article explains how to use it as a causal validation tool alongside network pharmacology in tumor angiogenesis research.

• CFDA SE Cell Tracer Kit: Practical Guide

  2026-09-19

  The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell proliferation studies, cell lineage tracing, and live-cell tracking. It is appropriate when covalent labeling must remain detectable for several days, but not when reversible marking, rapid dye clearance, or immediate physiological readouts are required.

• WST-8 Glucose Uptake Assay Kit Guide

  2026-09-18

  The WST-8 Glucose Uptake Assay Kit is a non-radioactive glucose uptake assay based on 2-deoxyglucose conversion, NADPH generation, and 450 nm formazan detection. Product information reports a working linearity of 10–500 μM under stated assay conditions, supporting quantitative cellular glucose metabolism studies.

• Beyond Viability: Measuring Cancer Drug Responses

  2026-09-18

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of an in vitro drug response. The framework encourages cancer researchers to combine endpoint and time-course measurements so that cytostatic effects are not mistaken for cell killing.

• Balsalazide in Active Ulcerative Colitis: Evidence Review

  2026-09-17

  This 2009 review examined balsalazide as a colon-targeted 5-aminosalicylate prodrug for mild-to-moderate active ulcerative colitis. Its central finding was that bacterial activation in the colon supports sustained 5-ASA delivery, with clinical evidence for remission induction, rapid symptom improvement, and tolerability comparable to other oral 5-ASA therapies.

• EdU Imaging Kits (Cy3): S-Phase Detection

  2026-09-17

  EdU Imaging Kits (Cy3) provide antibody-free detection of DNA synthesis during S phase through copper-catalyzed click chemistry. The 5-ethynyl-2'-deoxyuridine imaging kit supports fluorescence microscopy and flow cytometry while preserving morphology and antigen-accessible epitopes.

• Pazopanib in ATRX-Aware Glioma Assays

  2026-09-16

  Pazopanib (GW-786034) offers a powerful way to study RTK dependence, angiogenesis inhibition, and genotype-specific drug response in glioma models. This guide translates ATRX-focused evidence into assay decisions that distinguish cell-autonomous toxicity from vascular effects.

8372 records 1/559 page Next 12345 下5页 Last page